v3.26.1
Segment Information
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates as one operating segment, the research and development of its investigational drug product. The Company used the management approach to determine its reportable operating segment. The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer, who reviews financial information presented on a consolidated basis. The Company is a clinical-stage pharmaceutical company. The CODM uses net loss as a measure of profit and loss, and assesses Company performance through the achievement of its clinical development goals. The CODM is regularly provided with budgeted and forecasted expense information which is used to determine the Company’s liquidity needs and cash allocation to its development programs. The CODM uses cash and marketable securities as a measure of segment assets in managing the enterprise.

The Company had no revenue during the three months ended March 31, 2026 and 2025. Depreciation and amortization expense was $2 thousand and $43 thousand for the three months ended March 31, 2026 and 2025, respectively. The following table illustrates our segment information for significant operating expenses and includes a reconciliation to net loss for the three months ended March 31, 2026 and 2025:
 Three Months Ended March 31
 20262025
Operating Expenses:
Research and development by significant expense:
  BOLSTER trial$(50)$788 
  ASCEND trial174 21 
  Chemistry, manufacturing and controls191 220 
  Clinical department768 1,156 
  Other (1)
121 417 
Research and development1,204 2,602 
General and administrative by significant expense:
  Corporate1,333 1,144 
  Investor relations/public relations/communications237 331 
  Finance585 629 
  Legal1,094 224 
  Business development149 127 
  Share based compensation expense293 404 
  Other (2)
47 386 
General and administrative3,738 3,245 
Operating loss(4,942)(5,847)
Other income, net66 161 
Benefit from income taxes(387)(962)
Net loss$(4,489)$(4,724)
Cash and marketable securities$13,060 $25,833 
 (1) Included in Other are the GBM study, FORTIFIDE study and research
     oncology expenses
 (2) Included in Other are facilities expense, human resource
     and information technology expenses